Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Revisiting ASCOT 16 years later

The Anglo-Scandinavian Cardiovascular Outcomes Trial (ASCOT) was a prospective, randomised, open-label trial with a blinded endpoint and a double-blind 2 × 2 factorial component. ASCOT tested the primary hypothesis that the calcium channel blocker amlodipine (with perindopril as required) would be more effective for preventing coronary heart disease than the β-blocker atenolol (with or without a diuretic). People with hypertension in the UK, Ireland, and Nordic countries (n=19 342) were randomly assigned within blood pressure-lowering arm (BPLA).